Amundi’s Pacira BioSciences PCRX Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q3
$507K Buy
20,224
+4,330
+27% +$110K ﹤0.01% 1654
2026
Q2
$403K Buy
15,894
+2,210
+16% +$52.2K ﹤0.01% 1726
2026
Q1
$309K Buy
+13,684
New +$304K ﹤0.01% 1733
2025
Q2
– Sell
-18,723
Closed -$455K – 2039
2025
Q1
$455K Sell
18,723
-4,391
-19% -$105K ﹤0.01% 1512
2024
Q4
$429K Buy
23,114
+15,431
+201% +$271K ﹤0.01% 1591
2024
Q3
$120K Buy
7,683
+711
+10% +$12.2K ﹤0.01% 1755
2024
Q2
$151K Buy
+6,972
New +$198K ﹤0.01% 1633
2022
Q4
– Sell
-2,635
Closed -$149K – 1956
2022
Q3
$149K Hold
2,635
– – ﹤0.01% 1498
2022
Q2
$139K Hold
2,635
– – ﹤0.01% 1400
2022
Q1
$214K Hold
2,635
– – ﹤0.01% 1380
2021
Q4
$162K Hold
2,635
– – ﹤0.01% 1507
2021
Q3
$148K Hold
2,635
– – ﹤0.01% 1476
2021
Q2
$160K Buy
+2,635
New +$167K ﹤0.01% 1422

Other funds holding PCRX

Amundi's PCRX Position: Q3 2026 in Review

Amundi increased its Pacira BioSciences (PCRX) stake by 27% in Q3 2026, buying an estimated $110K and bringing the position to 20,224 shares worth $507K. The position accounts for ﹤0.01% of the portfolio, ranked #1654.

Amundi first reported a position in PCRX in Q2 2021 and has held it in 13 quarters since. 258 funds tracked by Wall St. Rank hold PCRX as of Q3 2026.

  • Amundi held 20,224 shares of Pacira BioSciences worth $507K as of Q3 2026.
  • Amundi bought 4,330 Pacira BioSciences shares in Q3 2026, an estimated $110K.
  • Pacira BioSciences made up ﹤0.01% of Amundi's portfolio in Q3 2026, its #1654 holding.
  • Amundi first reported a position in Pacira BioSciences in Q2 2021 and has held it in 13 quarters since.
  • 258 funds tracked by Wall St. Rank held Pacira BioSciences as of Q3 2026.

Based on Amundi's 13F filing for Q3 2026, filed 6 Nov 2026.